Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.69 (
botulinum neurotoxin
)
1,901
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Rapid treatment (1 min) of rat striatal synaptosomes with low-dose amphetamine increases surface expression of the
dopamine transporter
(
DAT
). Using mouse neuroblastoma N2A cells, stably transfected with green fluorescent protein-
DAT
, we demonstrate the real-time substrate-induced rapid trafficking of
DAT
to the plasma membrane using total internal reflection fluorescence microscopy (TIRFM). Both the physiological substrate, dopamine, and amphetamine began to increase surface
DAT
within 10 s of drug addition and steadily increased surface
DAT
until removal 2 min later. The substrate-induced rise in surface
DAT
was dose-dependent, was blocked by cocaine, and abated after drug removal. Although individual vesicle fusion was not visually detectable, exocytosis of
DAT
was blocked using both tetanus neurotoxin and
botulinum neurotoxin
C to cleave soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins. Notably, the dopamine-induced increase in surface
DAT
was cocaine-sensitive but D(2)-receptor independent. TIRFM data were confirmed in human
DAT
-N2A cells using biotinylation, and similar effects were detected in rat striatal synaptosomes. A specific inhibitor of protein kinase C-beta blocked the substrate-mediated increase in surface
DAT
in both
DAT
-N2A cells and rat striatal synaptosomes. These data demonstrate that the physiological substrate, dopamine, and amphetamine rapidly increase the trafficking of
DAT
to the surface by a mechanism dependent on SNARE proteins and protein kinase C-beta but independent of dopamine D(2) receptor activation. Importantly, this study suggests that the reuptake system is poised to rapidly increase its function during dopamine secretion to tightly regulate dopaminergic neurotransmission.
...
PMID:Dopamine and amphetamine rapidly increase dopamine transporter trafficking to the surface: live-cell imaging using total internal reflection fluorescence microscopy. 1927 70
We investigated the functional relationship between the soluble N-ethylmaleimide-sensitive factor attachment receptor (SNARE) protein syntaxin 1A (syn 1A) and the
dopamine transporter
(
DAT
) by treating rat striatal tissue with Botulinum Neurotoxin C (
BoNT
/C) and co-transfecting syn 1A with
DAT
in non-neuronal cells, followed by analysis of
DAT
activity, phosphorylation, and regulation. Treatment of striatal slices with
BoNT
/C resulted in elevated dopamine (DA) transport Vmax and reduced
DAT
phosphorylation, while heterologous co-expression of syn 1A led to reduction in
DAT
surface expression and transport Vmax. Syn 1A was present in
DAT
immunoprecipitation complexes, supporting a direct or indirect interaction between the proteins. Phorbol ester regulation of DA transport activity was retained in
BoNT
/C-treated synaptosomes and syn 1A transfected cells, demonstrating that protein kinase C (PKC) and syn 1A effects occur through independent processes. These findings reveal a novel mechanism for regulation of
DAT
activity and phosphorylation, and suggest the potential for syn 1A to impact DA neurotransmission through effects on reuptake.
...
PMID:Syntaxin 1A regulates dopamine transporter activity, phosphorylation and surface expression. 2064 91